false
0001760542
0001760542
2025-01-29
2025-01-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 29, 2025
HOOKIPA
Pharma Inc.
(Exact name of registrant as specified
in its Charter)
| Delaware |
|
001-38869 |
|
81-5395687 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
350
Fifth Avenue, 72nd Floor,
Suite
7240 |
|
|
| New
York,
New
York |
|
10118 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: +43 1
890 63 60
Not applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instructions A.2. below):
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each
class |
|
Trading
Symbol(s) |
|
Name of each
exchange
on which registered |
| Common
Stock, $0.0001 par value per share |
|
HOOK |
|
The
Nasdaq Capital
Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On December 27, 2024, HOOKIPA Pharma Inc.
(the “Company”) filed a petition (the “Section 205 Proceeding”) in the Delaware Court of Chancery (the “Court
of Chancery”) pursuant to Section 205 of the Delaware General Corporation Law (the “DGCL”) seeking an order validating
and declaring effective certain actions taken by the Company’s stockholders at the Company’s 2022 Annual Meeting of Stockholders
(the “2022 Annual Meeting”) and 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”), as described
below. The Section 205 Proceeding is captioned In re HOOKIPA Pharma Inc., C.A. No. 2024-1346-KSJM. A copy of the Company’s
petition filed in the Section 205 Proceeding is attached hereto as Exhibit 99.1 and incorporated herein by reference.
At the 2022 Annual Meeting, the Company’s
stockholders approved, among other things, proposals to (i) elect two Class III directors for three-year terms, (ii) amend
the Company’s certificate of incorporation to increase the total number of authorized shares of common stock from 100,000,000 shares
to 200,000,000 shares, and (iii) amend the Company’s 2019 Stock Option and Incentive Plan (collectively, the “2022 Stockholder
Actions”). The proposals are described more fully in the Company’s definitive proxy statement for the 2022 Annual Meeting,
filed with the Securities and Exchange Commission (“SEC”) on May 16, 2022, and the voting results from the meeting are
set forth in the Company’s Current Report on Form 8-K filed with the SEC on July 1, 2022. The record date established
for the 2022 Annual Meeting was April 13, 2022, which was 78 days before the date of the 2022 Annual Meeting, which was held on June 30,
2022. Under the DGCL, the record date should have been set for no sooner than Sunday, May 1, 2022, which was the 60th day before
the 2022 Annual Meeting.
At the 2023 Annual Meeting, the Company’s
stockholders approved, among other things, a proposal to elect three Class I directors for three-year terms (the “2023 Stockholder
Action”). The proposal is described more fully in the Company’s definitive proxy statement for the 2023 Annual Meeting, filed
with the SEC on April 13, 2023, and the voting results from the meeting are set forth in the Company’s Current Report on Form 8-K
filed with the SEC on June 9, 2023. The record date established for the 2023 Annual Meeting was April 4, 2023, which was 66
days before the date of the 2023 Annual Meeting, which was held on June 9, 2023. Under the DGCL, the record date should have been
set for no sooner than Monday, April 10, 2023, which was the 60th day before the 2023 Annual Meeting.
The Section 205 Proceeding seeks to validate
the 2022 Stockholder Actions and the 2023 Stockholder Action pursuant to Section 205 of the DGCL.
On January 15, 2025, the Court of Chancery
approved the Company’s motion to expedite the Section 205 Proceeding and directed the Company to file this Form 8-K to
notify stockholders that the Court of Chancery will hold a final hearing to consider the merits of the petition filed by the Company in
the Section 205 Proceeding on February 14, 2025, at 1:30 p.m. Eastern Time, at the New Castle County Courthouse, 500 North
King Street, Wilmington, DE 19801 (the “Section 205 Hearing”). This Form 8-K constitutes notice of the Section 205
Hearing. If any stockholder of the Company wishes to express a position on the Section 205 Proceeding, such stockholders of the Company
may (i) appear at the hearing in the Section 205 Proceeding or (ii) file a written submission with the Register in Chancery,
New Castle County Courthouse, 500 North King Street, Wilmington, DE 19801, referring to the case caption, In re HOOKIPA Pharma Inc.,
C.A. No. 2024-1346-KSJM, in advance of the Section 205 Hearing, and any such written submission should be emailed to the Company’s
counsel, D. McKinley Measley, Morris, Nichols, Arsht & Tunnell LLP, at dmeasley@morrisnichols.com.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 29, 2025 |
HOOKIPA Pharma Inc. |
| |
|
|
| |
By: |
/s/ Terry Coelho |
| |
Name: |
Terry Coelho |
| |
Title: |
Executive Vice President and Chief Financial Officer |
Exhibit 99.1
IN THE COURT OF CHANCERY FOR
THE STATE OF DELAWARE
| |
) |
|
| IN RE HOOKIPA PHARMA INC. |
) |
C.A. No. |
| |
) |
|
VERIFIED PETITION FOR
RELIEF UNDER 8 DEL. C. § 205
Petitioner
HOOKIPA Pharma Inc. (the “Company”) brings this Petition for relief under Section 205 (“Section 205”)
of the Delaware General Corporation Law (the “DGCL”):
NATURE OF THE ACTION
1. In
connection with holding its annual meetings of stockholders for calendar years 2022 (the “2022 Meeting”) and 2023
(the “2023 Meeting”), the Board of Directors of the Company mistakenly fixed record dates that were more than 60 days
before the dates of the meetings, in contravention of Section 213(a) of the DGCL. For the 2022 Meeting, the record date was
78 days before the meeting, and, for the 2023 Meeting, the record date was 66 days before the meeting.
2. Through
this Petition, the Company seeks to validate four actions approved by Company stockholders:
| (i) | an amendment
to the Company’s Certificate of Incorporation (the “Charter”) to
increase the number of shares of Company common stock authorized for issuance (the “2022
Share Increase Amendment”), which was adopted by stockholders at the 2022 Meeting; |
| (ii) | an amendment
to the Company’s 2019 Stock Option and Incentive Plan (the “Plan Amendment”),
which was adopted by stockholders at the 2022 Meeting; |
| (iii) | the election
of two directors for three-year terms at the 2022 Meeting (the “2022 Elections”);
and |
| (iv) | the election
of three directors for three-year terms at the 2023 Meeting (the “2023 Elections”). |
| 3. | The Company
respectfully submits that relief under Section 205 is warranted: |
| · | The
stockholder votes were fully informed, and the proxy materials for each meeting included
detailed descriptions of each action. Accordingly, the Company believes the equities favor
validating the stockholder votes at these meetings. |
| · | It
is unclear whether the Company could seek stockholder approval to ratify these actions using
Section 204 of the DGCL (“Section 204”). The Company has potentially
overissued shares in reliance on the 2022 Share Increase Amendment, calling into question
which shares of Company stock are valid and entitled to vote on a Section 204 ratification. |
BACKGROUND ON THE MEETINGS
AND PROPOSALS
4. Meeting,
Notice and Record Dates. With respect to the 2022 Meeting and the 2023 Meeting:
| |
|
|
|
The # of voting |
The # of voting |
| |
|
Notice of the |
The record date |
shares |
shares deemed |
| |
The meeting |
meeting was |
for the meeting |
outstanding on |
present at the |
| |
was held on: |
given on: |
was: |
the record date |
Meeting was: |
| |
|
|
|
was:1 |
|
| 2022 Meeting |
June 30, 2022 |
May 16, 2022 |
April 13, 2022 |
50,872,734 |
39,569,251 |
| |
|
|
(78 days before |
shares of |
(77% of shares |
| |
|
|
the meeting) |
common stock |
outstanding the |
| |
|
|
|
|
on record date) |
| 2023
Meeting |
June 9,
2023 |
April 13,
2023 |
April 4,
2023 |
52,322,822 |
36,732,133 |
| |
|
|
(66
days before |
shares
of |
(70%
of shares |
| |
|
|
the
meeting) |
common
stock |
outstanding
the |
| |
|
|
|
|
on
record date) |
| 1 | During
the time periods described in this Petition, the Company also has had issued and outstanding
shares of Class A common stock and series of preferred stock, but these classes and
series were not non-voting on the actions described in this Petition. |
5. Issues
with the Record Dates. Section 213(a) of the DGCL specifies
that a record date cannot be earlier than the 60th day nor less than the 10th day before the date of a
stockholder meeting. For the 2022 Meeting, the record date should have been
fixed for no earlier than May 1st, instead of April 13th. For the 2023 Meeting, the record
date should have been fixed for no earlier than April 10th, instead of April 4th. These record date
defects are the only failures of authorization (as that term is used in Section 204) for the actions the Company wishes to
validate.
6. Proposals
submitted for stockholder approval. The proposals presented for stockholder approval were as follows:
| 2022
Meeting |
2023
Meeting |
| |
|
| 1. Election of two directors to three-year terms (Directors
Julie O’Neill and Reinhard Kandera) |
1. Election of three directors to three-year terms (Directors
Joern Aldag, Jan Van de Winkel and David Kaufman) |
| 2.
Ratification of auditor |
2.
Ratification of auditor |
| 3.
Proposal to amend the Charter to increase the total number
of shares of common stock authorized for issuance
from 100 million to 200 million shares (i.e., the 2022
Share Increase Amendment) |
|
| 4.
Proposal to authorize an amendment to the Charter to effect
a reverse stock split of Company common stock in
the range of 1-for-2 to 1-for-10 |
|
| 5.
Proposal to amend the Company’s 2019 Stock Option and
Incentive Plan by 1,000,000 s[]hares (i.e., the Plan Amendment) |
|
Of
these actions, the Company seeks to validate only the 2022 Share Increase Amendment, the Plan Amendment, the 2022 Elections and the 2023
Elections.2
| 2 | The
Company did not pursue a reverse split of its stock following the 2022 Meeting, even though
it solicited stockholder authorization for a reverse split. |
7. The
2022 Share Increase Amendment. The 2022 Share Increase Amendment provided for an increase in the number of shares of common stock
that the Company is authorized to issue from 100 million to 200 million. This amendment required approval from the holders of a majority
of the common stock issued and outstanding. The 2022 Share Increase Amendment was approved by the holders of 31,364,292 shares of common
stock, representing over 61% of the common stock outstanding as of the April 13, 2022 record date. In the proxy statement, the Company
stated that brokers were entitled to vote on the amendment absent instructions from the beneficial owners, and the voting results of
the meeting reflect that brokers voted on the amendment. Believing it had obtained valid stockholder approval, the Company filed a certificate
of amendment to enact the 2022 Share Increase Amendment with the Office of the Secretary of State of the State of Delaware on June 30,
2022, which was the same day as the 2022 Meeting.
8. The
Plan Amendment. The Plan Amendment increased, from 4,878,814 to 5,878,814, the number of shares that the Company could use to
award equity grants to employees and certain agents under the Incentive Plan. The amendment enacted other changes described in the
proxy statement for the 2022 Meeting, and a clean copy of the entire 2019 Stock Option and Incentive Plan, as it would be amended by
the Plan Amendment, was attached as an exhibit to the proxy statement. To be adopted, the votes cast “for” the Plan
Amendment needed to exceed the votes cast “against” the Plan Amendment at a meeting at which a quorum was present. A
quorum was present at the 2022 Meeting, with over 77% of the common stock present in person or by proxy, and the Plan Amendment was
approved by over 73% of the votes cast (with the holders of 23,315,702 shares voting in favor, and 8,422,262 shares voting against).
The proxy materials for the meeting disclosed that brokers were not entitled to exercise discretionary authority to vote on the
proposal, and broker non-votes had no effect on the outcome of the proposal given the voting standard. The voting results list
broker non-votes, thereby confirming that brokers did not vote.
9. The
2022 Elections. The stockholders voted to elect two directors for three-year terms at the 2022 Meeting. Company directors are elected
by plurality vote, and the Company’s nominees ran unopposed. Each candidate received “for” votes representing at least
65% of the shares present in person or represented by proxy at the 2022 Meeting.
10. The
2023 Elections. The stockholders voted to elect three directors for three-year terms at the 2023 Meeting. Company directors are
elected by plurality vote, and the Company’s nominees ran unopposed. Each candidate received “for” votes
representing at least 60% of the shares present in person or represented by proxy at the 2023 Meeting.
CAPITALIZATION STRUCTURE
ISSUES
11.
Calculating the number of clearly valid shares outstanding. If the 2022 Share
Increase Amendment did not validly increase the number of shares of common stock authorized for issuance to 200 million, then (absent
validation by this Court), the Company is limited to validly issuing only 100 million shares of common stock (the maximum number fixed
in the non-amended Charter). To determine the number of shares that a corporation may issue on a given date, Section 161 of the
DGCL requires the Company to deduct from its total number of authorized shares the number of shares that have already been issued plus
the number of shares that have been subscribed for or otherwise committed to be issued.3
The Company has a reserved a significant number of shares of common stock to satisfy the conversion rights of another class of common
stock, the conversion rights of several series of preferred stock and the exercise rights of equity grants.
| 3 | 8
Del. C. § 161 (“The directors may, at any time and from time to time, if
all of the shares of capital stock which the corporation is authorized by its certificate
of incorporation to issue have not been issued, subscribed for, or otherwise committed to
be issued, issue or take subscriptions for additional shares of its capital stock up to the
amount authorized in its certificate of incorporation.”). |
12. Number
of shares outstanding and reserved. By April 22, 2024, the record date for the Company’s annual meeting of stockholders
for calendar year 2024 (the “2024 Meeting”), there were 96,550,590 shares of common stock outstanding and 40,052,621
shares reserved for issuance. This total represents an over-issuance of shares of 36,603,211 ((96,550,590 + 40,052,621) – 100,000,000).
The Company’s stock is traded on The Nasdaq Capital Market, and the composition of its significant stockholders has changed over
time. Accordingly, the Company cannot determine with certainty which outstanding shares are valid and which outstanding shares are potentially
invalid.
13. Subsequent
Actions. The Company held the 2024 Meeting on June 17, 2024. There were no issues with the record date for the 2024 Meeting.
| · | At the 2024 Meeting, the Company stockholders acted to (i) elect
directors, (ii)
ratify the selection of the Company’s auditor, (iii) approve an amendment to the Charter to further increase the number
of shares of common stock authorized for issuance from 200 million to 400 million (the “2024 Share Increase
Amendment”) and (iv) authorized the Company to effect a reverse stock split within a range of 1-for-2 to 1-for-10
shares of common stock. |
| · | The
Company obtained stockholder approval for each of these actions. |
| · | Relying
on these stockholder approvals, the Company caused the amendment to the Charter effecting
the 2024 Share Increase Amendment to be filed with the Office of State of the State of Delaware
on June 18, 2024. |
| · | The
Company filed another amendment to the Charter with such Office on July 9, 2024, to
effect a 1-for-10 reverse stock split of the common stock (the “2024 Reverse Stock
Split”). |
14. The 2024 Share Increase Amendment and the 2024 Reverse Stock Split are fundamental transactions that affect the Company’s capitalization.
However, as noted above, the Company cannot determine with certainty which shares reflected on the Company’s books as outstanding
on the record date for the 2024 Meeting are valid and which shares are potentially invalid. Accordingly, the validity of the actions
taken by the Company stockholders at the 2024 Meeting are also called into question. The Company is not seeking validation of these actions.
However, if the Court validates the actions taken at the 2022 Meeting with retroactive effect (as requested in this Petition) any uncertainty
about the validity of the acts taken at the 2024 Meeting will be resolved.
CONSIDERATIONS WARRANTING
RELIEF UNDER SECTION 205
15. The record date was fixed with the subjective belief that it complied with the DGCL. The Board of Directors fixed the record dates
for the 2022 Meeting and 2023 Meeting that were selected by management. Counsel reviewed the proxy materials for compliance with applicable
law. The Company did not learn about the record date issues until December 9, 2024, when the Company received a letter from an attorney
purporting to represent a stockholder of the Company. Counsel for the purported stockholder has indicated that the purported stockholder
intends to take no position with respect to the relief sought in this action pursuant to Section 205.
16.
The Company and its stockholders treated the record date as valid. The Company treated the record dates for the 2022 Meeting and
2023 Meeting as valid when the Company expended the time and cost to prepare the proxy materials for those meetings and to hold those
meetings. The stockholders as of April 13, 2022 and April 4, 2023 also relied on those record dates to review the proxy materials
and to cast a vote on the proposals submitted at those meetings. The Company, purchasers of its stock and the holders of its convertible
securities and equity grants relied on the validity of the 2022 Share Increase Amendment. The Company and its stockholders, in turn,
relied on the validity of the shares issued under the 2022 Share Increase Amendment to hold the 2024 Meeting and to take the fundamental
actions adopted during there, including the 2024 Share Increase Amendment and the 2024 Reverse Split.
17.
Harm resulting from no validation. The Company is not aware of any harm that will result from the validations requested in this
Petition. Instead, several groups of Company stakeholders will benefit from the validations. The validations will place the Company and
its security holders in the position they have always thought they were in vis-à-vis the Company’s capitalization table.
The fully informed stockholder votes taken at the 2022 Meeting and 2023 Meeting will also be given full effect rather than nullified.
18. Recourse
to Section 204. The Company is mindful of precedents encouraging corporations to rely on Section 204 when possible. But
the Company respectfully submits that recourse to Section 204 likely is not available and is not warranted here.
| · | The
Courts have denied Section 205 petitions where an invalid act was never approved by
stockholders or was approved by the incorrect vote. Requiring the use of Section 204
in those instances enfranchised stockholders. Here, the stockholders already had their say
at the 2022 Meeting and 2023 Meeting and returned enough “for” votes to satisfy
the applicable voting standards. |
| · | The
Courts have also denied Section 205 relief where a stockholder vote was obtained but inaccurate disclosure undermined the integrity
of the vote. In 1847 Goedeker Inc., for example, a corporation solicited approval of charter amendments and incorrectly informed
beneficial owners that brokers could not vote on the amendments absent instruction from the beneficial owners.4 This meant
beneficial owners were told that providing no instruction equated to a vote against the amendments. In reality, the brokers later voted
for the amendments. There is no similar disclosure problem here. |
| · | A
78-day and 66-day period between a record date and meeting date does not offend public policy. A corporation is expressly permitted by
Section 213 to convene a meeting on the 60th day after a record date and is then expressly permitted by Section 222
to adjourn the meeting for an additional 30 days before taking a stockholder vote.5 A new record date is not required for
the adjourned meeting.6 The DGCL therefore contemplates at
least a 90-day period between a record date and taking a vote. The record dates at issue here may not have technically complied with
the DGCL, but they are not per se stale. |
| 4 | C.A.
No. 2022-0219-SG (oral ruling May 27, 2022), attached as Exhibit A
hereto. |
| 5 | 8
Del. C. § 222(c) (“Unless the bylaws otherwise require, when a meeting
is adjourned to another time or place . . . notice need not be given of the adjourned meeting
if the time, place, if any, thereof . . . are (i) announced at the meeting at which
the adjournment is taken . . . . At the adjourned meeting the corporation may transact any
business which might have been transacted at the original meeting.”). |
| 6 | 8
Del. C. § 213(a) (“A determination of stockholders of record entitled
to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the
meeting; provided, however, that the board of directors may fix a new record date . . . .”). |
| · | It
is possible that a significant number of shares of common stock issued since the adoption
of the 2022 Share Increase Amendment are invalid. Shares of common stock are traded on The
Nasdaq Capital Market. These potentially invalid shares cannot be traced or identified. In
light of these issues, the Company respectfully submits that Section 204 is practicably
unavailable. |
19. For
these reasons, the Company respectfully requests the relief it seeks pursuant to Section 205.
COUNT ONE
20. The
Company repeats and reiterates the allegations above as if set forth fully herein.
21. Because
of the potential defects above, there is uncertainty as to the validity of 2022 Share Increase Amendment, the Plan Amendment, the 2022
Elections and the 2023 Elections, each of which is a potentially defective corporate act.
22. This
Court has the authority under Section 205(a)(3) to determine the validity and effectiveness of any defective corporate act
not ratified pursuant to Section 204 and under Section 205(b)(2) to validate and declare effective any defective corporate
act.
23. The
Company effected the actions for which it seeks validation with a good faith belief that they were validly approved by the stockholders.
24. The
Company and its stockholders have treated as valid the record dates that resulted in the issues with the validity of the actions taken
at the 2022 Meeting and 2023 Meeting.
25. On
information and belief, no persons would be harmed by the validation requested here.
| 26. | The Company
has no adequate remedy at law. |
PRAYER FOR RELIEF
WHEREFORE, the Company
respectfully requests that this Court enter a proposed Final Order Granting Relief Under 8 Del. C. § 205 in the form
attached hereto:
| A. | Validating
and declaring effective, retroactive to the date of the 2022 Meeting, the 2022 Share Increase
Amendment, the Plan Amendment and the 2022 Elections; and |
| B. | Validating
and declaring effective, retroactive to the date of the 2023 Meeting, the 2023 Elections;
and |
| C. | Granting such
other and further relief as this Court deems proper. |
| |
MORRIS, NICHOLS, ARSHT & TUNNELL LLP |
|
| |
|
|
| OF COUNSEL: |
/s/ D. McKinley Measley |
|
| D. McKinley Measley
(#5108) |
|
| COOLEY LLP |
Alec F. Hoeschel (#7066) |
|
| 1201 N. Market Street |
|
| Peter Adams |
Wilmington, DE 19801 |
|
| (302) 658-9200 |
|
| 10265 Science Center Drive |
dmeasley@morrisnichols.com |
|
| San Diego, CA 92121-1117 |
ahoeschel@morrisnichols.com |
|
| (858) 550 6059 |
Attorneys for Petitioner |
|
| Sarah Lightdale |
|
| |
|
| 55 Hudson Yards |
|
|
| New York, New York 10001-2157 |
|
|
| (212) 479 6000 |
|
|
| |
|
|
| December 27, 2024 |
|
|
v3.24.4
Cover
|
Jan. 29, 2025 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Jan. 29, 2025
|
| Entity File Number |
001-38869
|
| Entity Registrant Name |
HOOKIPA
Pharma Inc.
|
| Entity Central Index Key |
0001760542
|
| Entity Tax Identification Number |
81-5395687
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
350
Fifth Avenue, 72nd Floor
|
| Entity Address, Address Line Two |
Suite
7240
|
| Entity Address, City or Town |
New
York
|
| Entity Address, State or Province |
NY
|
| Entity Address, Postal Zip Code |
10118
|
| City Area Code |
+43
|
| Local Phone Number |
1
890 63 60
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common
Stock, $0.0001 par value per share
|
| Trading Symbol |
HOOK
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From May 2025 to Jun 2025
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Jun 2024 to Jun 2025
